225 related articles for article (PubMed ID: 11729566)
1. Impact of the "new science" of genomics.
Coile RC
J Healthc Manag; 2001; 46(6):365-8. PubMed ID: 11729566
[No Abstract] [Full Text] [Related]
2. In tough times, personalized medicine needs specific partners.
Ballantyne C
Nat Med; 2008 Dec; 14(12):1294. PubMed ID: 19057535
[No Abstract] [Full Text] [Related]
3. Prescription for an ailing pharmaceutical industry.
Demain AL
Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
[No Abstract] [Full Text] [Related]
4. The biotechnology industry: What's next?
Guertin PA
Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
[No Abstract] [Full Text] [Related]
5. The 802 million dollars fallacy.
Hodgson J
Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
[No Abstract] [Full Text] [Related]
6. Realizing potential: the state of Asian bioentrepreneurship.
Tang CM; Mahmud MA; Foo FK; Chu SY; Chiu RI; Tanticharoen M; Zhang L; Chang TW
Nat Biotechnol; 2003 Jul; 21 Suppl():BE15-22. PubMed ID: 12874972
[No Abstract] [Full Text] [Related]
7. Legal row looms for gene-map firm.
Dalton R
Nature; 2003 May; 423(6939):470. PubMed ID: 12774085
[No Abstract] [Full Text] [Related]
8. White biotech and the financial crisis.
Rabinovich M
Biotechnol J; 2009 Aug; 4(8):1117-23. PubMed ID: 19685465
[No Abstract] [Full Text] [Related]
9. Rediscovering plant-based drugs.
Littleton J; Falcone D; Davies HM
Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
[No Abstract] [Full Text] [Related]
10. Bioprospectors turn their gaze to Canada.
Dalton R
Nature; 2002 Oct; 419(6909):768. PubMed ID: 12397317
[No Abstract] [Full Text] [Related]
11. Biotech business Down Under.
Beckley C
Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
[No Abstract] [Full Text] [Related]
12. Life support for life science innovation?
Nat Biotechnol; 2007 Feb; 25(2):144. PubMed ID: 17287731
[TBL] [Abstract][Full Text] [Related]
13. HGS drug flop latest genomics setback.
Reid B
Nat Biotechnol; 2002 Jun; 20(6):533. PubMed ID: 12042841
[No Abstract] [Full Text] [Related]
14. Avoiding the genomics divide.
Calva E; Cardosa MJ; Gavilondo JV
Trends Biotechnol; 2002 Sep; 20(9):368-70. PubMed ID: 12175761
[No Abstract] [Full Text] [Related]
15. Evolving symbiosis--venture capital and biotechnology.
Bradford TC
Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
[No Abstract] [Full Text] [Related]
16. Hyseq-Variagenics merger signals end of the line.
Hodgson J
Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
[No Abstract] [Full Text] [Related]
17. US venture capital for biotechnology.
Dibner MD; Trull M; Howell M
Nat Biotechnol; 2003 Jun; 21(6):613-7. PubMed ID: 12776144
[No Abstract] [Full Text] [Related]
18. US government previews biotech survey.
Goho A
Nat Biotechnol; 2003 Aug; 21(8):837-8. PubMed ID: 12894185
[No Abstract] [Full Text] [Related]
19. Hedge funds gain edge by doubling biotech investments.
Ransom J
Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
[No Abstract] [Full Text] [Related]
20. Biotech holds its own in Q2.
Lawrence S
Nat Biotechnol; 2004 Aug; 22(8):938. PubMed ID: 15286634
[No Abstract] [Full Text] [Related]
[Next] [New Search]
